AuntMinnie

SEPTEMBER 13, 2023

Read more on AuntMinnie.com Related Reading: ACR urges full coverage for amyloid PET scans CMS proposal covers PET scans for Alzheimer’s disease MITA praises FDA for Leqembi approval FIND Act reintroduced in U.S. Senate MITA hails radiopharmaceutical legislation

Radiopharmaceuticals 52

Radiopharmaceuticals PET Scan Medical Imaging Disease 52

Imaging Technology

JANUARY 5, 2024

This leading radiopharmaceutical platform provides detailed PET imaging-based diagnosis and dosimetry using long-lived copper-64 ( 64 Cu) for imaging and alpha-particle targeted RPT using lead-212 ( 212 Pb). milla1cf Fri, 01/05/2024 - 11:21 January 5, 2024 — Perspective Therapeutics, Inc.

Radiopharmaceuticals 87

Radiopharmaceuticals Clinic Nuclear Medicine Radiation 87

Imaging Technology

APRIL 5, 2024

milla1cf Fri, 04/05/2024 - 11:31 April 5, 2024 — RLS Radiopharmacies , America’s only Joint Commission-accredited radiopharmacy network, today announced it has expanded its radiopharmaceutical contract development and manufacturing (rCDMO) capabilities by entering into a strategic agreement with global isotope technology leader Eckert & Ziegler.

Radiopharmaceuticals 52

Radiopharmaceuticals Radiation Oncology Radiation Quality and Compliance 52

Open Medscience

AUGUST 9, 2024

Radiopharmacy combines the disciplines of pharmacy and nuclear science to create radiopharmaceuticals, revolutionising the diagnosis and treatment of diseases. The post Radiopharmacy: Harnessing Radioactive Compounds for Diagnosis and Treatment appeared first on Open MedScience.

Radiopharmaceuticals 52

Radiopharmaceuticals Disease 52

AuntMinnie

JULY 10, 2024

Centers for Medicare and Medicaid Services (CMS) proposed a new reimbursement plan July 10 for diagnostic PET scans that would provide separate payments for radiopharmaceuticals, as well as an extra payment for hospitals when they use domestically produced technetium-99m (Tc-99m).

Nuclear Medicine 122

Nuclear Medicine Radiopharmaceuticals Imaging Medicare 122

Imaging Technology

JANUARY 5, 2024

milla1cf Fri, 01/05/2024 - 11:32 January 5, 2024 — NorthStar Medical Radioisotopes, LLC , a global innovator in development, production and commercialization of radiopharmaceuticals used to detect and treat cancer and other serious diseases, and Curadh MTR Inc. Chief Executive Officer of NorthStar Medical Radioisotopes.

Radiopharmaceuticals 52

Radiopharmaceuticals Medical Nuclear Medicine Pharmaceutical 52

Open Medscience

AUGUST 11, 2024

Pittsburgh Compound-B allows researchers to visualise amyloid plaques in the brain, aiding in Alzheimer's disease diagnosis and study. The post The Discovery and Development of Pittsburgh Compound-B (PIB): A Breakthrough in Alzheimer’s Disease Research appeared first on Open MedScience.

Disease 40

Disease Nuclear Medicine Radiopharmaceuticals Imaging 40

AuntMinnie

APRIL 4, 2024

Life Molecular Imaging (LMI) and Sofie Biosciences have begun offering the Neuraceq ( florbetaben F-18) PET radiotracer produced at Sofie's radiopharmaceutical manufacturing site in Cleveland, Ohio. With this expansion, LMI continues driving commercial sales of Neuraceq around the U.S.

Radiopharmaceuticals 95

Radiopharmaceuticals Imaging Disease Diagnostic 95

AuntMinnie

AUGUST 20, 2024

Life Molecular Imaging and PharmaLogic Holdings have inked a partnership and licensing agreement to provide and distribute the imaging agent Neuraceq from PharmaLogic's radiopharmaceutical manufacturing site near Denver, CO. Neuraceq is a diagnostic agent cleared by the U.S. Food and Drug Administration (FDA) for PET imaging of the brain.

Radiopharmaceuticals 40

Radiopharmaceuticals Disease Diagnostic Clinic 40

Open Medscience

NOVEMBER 9, 2023

Alzheimer's disease stems from genetic mutations and lifestyle factors, leading to brain plaque accumulation and dementia. The post Unveiling the Complex Etiology and Innovative Diagnostic Approaches in Alzheimer’s Disease appeared first on Open Medscience.

Disease 59

Disease Diagnostic Nuclear Medicine Radiopharmaceuticals 59

AuntMinnie

AUGUST 2, 2024

CereMark Pharma, a radiopharmaceutical company focused on neurodegenerative diseases, is planning a phase III clinical trial later this year to investigate the novel PET imaging agent F-18 flornaptitril.

Radiopharmaceuticals 52

Radiopharmaceuticals Disease Clinic IT 52

AuntMinnie

AUGUST 12, 2024

SPECT/CT imaging can help manage patients undergoing radiopharmaceutical therapy (RPT) with Pluvicto for advanced prostate cancer, according to a study published August 8 in the Journal of Nuclear Medicine. Yet whether SPECT/CT can be used to determine disease progression or response has yet to be delineated, they noted.

Nuclear Medicine 104

Nuclear Medicine Bone Scan Disease Radiopharmaceuticals 104

AuntMinnie

JULY 10, 2024

Centers for Medicare and Medicaid Services (CMS) proposed a new reimbursement plan July 10 for diagnostic PET scans that would provide separate payments for radiopharmaceuticals, as well as an extra payment for hospitals when they use domestically produced technetium-99m (Tc-99m).

Medicare 52

Medicare Nuclear Medicine Radiopharmaceuticals Imaging 52

Imaging Technology

JUNE 10, 2024

More recently, she and her collaborators developed a PET imaging agent for vaso-occlusive crisis in sickle cell disease, recently approved for human studies by the FDA as an Investigational New Drug. Louis , Missouri, where she worked more than 20 years developing PET and radiopharmaceutical therapy agents.

Nuclear Medicine 90

Nuclear Medicine Radiopharmaceuticals Disease Imaging 90

Imaging Technology

MAY 14, 2024

Siemens Healthineers and UH will look to also advance the treatment of patients with Alzheimer’s disease and use theranostics—combining the approaches of diagnostics and therapeutics—to treat patients with advanced forms of certain cancers, as well as develop new magnetic resonance ( MR ) technologies. tesla and 3T scanners.

Hospital 111

Hospital Magnetic Resonance Imaging Radiopharmaceuticals Disease 111

Imaging Technology

APRIL 28, 2023

Molecular imaging enables doctors and clinicians to see inside the body with a non-invasive process, helping to diagnose and treat diseases such as cancer, cardiovascular disease , and neurological diseases. It uses biomarkers to highlight molecular changes, which can sometimes alert doctors to possible disease.

Healthcare 94

Healthcare Healthcare Radiopharmaceuticals PET Scan 94

Imaging Technology

AUGUST 31, 2023

milla1cf Thu, 08/31/2023 - 15:50 August 31, 2023 — NorthStar Medical Radioisotopes , LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals, and Curadh MTR Inc. Ac-225 for use in radiopharmaceutical therapy (RPT). actinium-225 (Ac-225). “As a company at the forefront of U.S.

Medical 96

Medical Radiopharmaceuticals Pharmaceutical Radiation 96

AuntMinnie

JUNE 9, 2024

Her research also contributed to FDA approval of Lu-177 DOTATATE for treating neuroendocrine tumors; recently, she and collaborators developed a PET imaging agent for vaso-occlusive crisis in sickle cell disease, which has been approved for human studies by the FDA as an Investigational New Drug (IND).

Nuclear Medicine 98

Nuclear Medicine Radiopharmaceuticals Disease Imaging 98

Imaging Technology

AUGUST 29, 2023

Alan Taylor , stated, “Large-scale manufacture of therapeutic Cu-67 from highly efficient, environmentally preferable electron accelerators is critical to overcome the widespread supply issues in the radiopharmaceutical industry, due to a heavy reliance on a small number of antiquated nuclear reactors.

Pharmaceutical 84

Pharmaceutical Radiopharmaceuticals Clinic Medical 84

Imaging Technology

DECEMBER 6, 2023

and Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today provided additional information regarding a March 2022 licensing and collaboration agreement between Philochem and Blue Earth Diagnostics. Chief Executive Officer of Blue Earth Diagnostics.

Diagnostic 102

Diagnostic Diagnostic Imaging Clinic Radiopharmaceuticals 102

Imaging Technology

AUGUST 23, 2023

SCINTIX therapy is a cutting-edge radiopharmaceutical-directed treatment applicable for early and late-stage cancers that uses the individual biology of each tumor to drive its own treatment. “We founder and CTO of RefleXion.

Radiopharmaceuticals 94

Radiopharmaceuticals Disease Radiation Clinic 94

AuntMinnie

FEBRUARY 12, 2024

Chinese clinicians have provided evidence in a “real-world study” that shows amyloid PET imaging is effective for diagnosing and managing patients with Alzheimer’s disease, according to a study published February 8 in Alzheimer’s and Dementia. of patients, noted lead author Ke-Liang Chen, MD, a neurologist at Fudan University.

PET Scan 104

PET Scan Diagnose Disease Radiopharmaceuticals 104

Imaging Technology

JANUARY 12, 2024

Other technologies use anatomical images to guide radiotherapy delivery; however, SCINTIX therapy is the only radiotherapy to use emissions from cancer cells, created by injecting the patient with a radiopharmaceutical, to deliver a radiation dose that continuously and autonomously targets the cancer itself.

Radiopharmaceuticals 104

Radiopharmaceuticals Radiation Medicare Clinic 104

Imaging Technology

AUGUST 28, 2023

This volume would be equivalent to 50% of today’s supply and would underpin the wider development of these targeted alpha therapy radiopharmaceuticals as an effective treatment modality for cancer", commented Sven Van den Berghe, PanTera’s Chief Executive Officer.

Radiopharmaceuticals 97

Radiopharmaceuticals Pharmaceutical Medical Clinic 97

Imaging Technology

JULY 5, 2023

Ac-225 is a high energy alpha-emitting radioisotope of increasing interest for clinical studies investigating the use of targeted radiopharmaceutical therapy, which combines select molecules with therapeutic radioisotopes to directly target and deliver therapeutic doses of radiation to destroy cancer cells in patients with serious disease.

Medical 69

Medical Radiopharmaceuticals Pharmaceutical Radiation 69

AuntMinnie

MARCH 25, 2024

Coronary artery disease (CAD) is the leading cause of mortality in the U.S. In a cohort of 1,282 patients who underwent invasive coronary angiography for suspected disease, noninvasive PET MPI performed within six months identified large perfusion defects (>10% of the left ventricular myocardium) in 82% of the patients.

Nuclear Medicine 128

Nuclear Medicine Radiopharmaceuticals Disease Radiation 128

AuntMinnie

JULY 29, 2024

In addition, the proposal includes a nuclear health center for processing medical isotopes produced by the reactor into radiochemicals, which will then be further processed into radiopharmaceuticals that can be administered to patients for the diagnosis and treatment of several diseases, including cancer, the commission said.

Medical 52

Medical Nuclear Medicine Radiopharmaceuticals Disease 52

Future Teleradiology

NOVEMBER 27, 2023

Advances in Cardiac Imaging: Precision in Heart Disease Diagnosis: Highlight recent breakthroughs in cardiac imaging within nuclear medicine. Novel Radiopharmaceuticals: Expanding Therapeutic Options: Highlight recent developments in novel radiopharmaceuticals.

Nuclear Medicine 52

Nuclear Medicine Radiopharmaceuticals Imaging Modalities Radiation 52

Imaging Technology

JANUARY 23, 2024

The machine will be used primarily for the manufacture of Strontium-82 for use in the diagnosis of cardiovascular disease, as well as for production of Germanium-68 for use in positron emission tomography (PET) imaging.

Radiopharmaceuticals 104

Radiopharmaceuticals Disease Diagnostic Clinic 104

Imaging Technology

JULY 5, 2024

mtaschetta-millane Fri, 07/05/2024 - 06:00 July 5, 2024 — Lantheus Holdings, Inc. ,

Diagnostic 97

Diagnostic Radiopharmaceuticals Disease IT 97

AuntMinnie

MARCH 26, 2024

Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. Since 2013 we've had several more radiopharmaceutical therapies get FDA approval.

Nuclear Medicine 122

Nuclear Medicine Radiopharmaceuticals Radiation Health Science 122

AuntMinnie

JANUARY 30, 2024

The timing of the new codes dovetails with advances in neuroimaging, such as in the assessment of white-matter diseases. A widely used class of radiopharmaceuticals in the study of the neuroinflammatory response targets the translocator protein (TSPO), according to the researchers.

MRI 105

MRI Radiopharmaceuticals Disease Imaging 105

Imaging Technology

APRIL 2, 2024

The availability of these offerings – including the MIM SurePlan and MIM Symphony families, MIM Maestro, MIM Encore, and more – is in alignment with GE HealthCare’s precision care strategy, which aims to deliver innovative digital solutions across care pathways for more precise, connected, and efficient care across disease states. "We

Healthcare 102

Healthcare Healthcare Radiation Oncology Magnetic Resonance Imaging 102

Imaging Technology

MAY 30, 2023

milla1cf Tue, 05/30/2023 - 19:49 May 30, 2023 — Blue Earth Diagnostics , a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals , today announced U.S. POSLUMA was developed to assist physicians in the detection and localization of prostate cancer.

Diagnostic 84

Diagnostic Imaging Radiopharmaceuticals Diagnostic Imaging 84

AuntMinnie

JUNE 20, 2024

Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. Since 2013 we've had several more radiopharmaceutical therapies get FDA approval.

Nuclear Medicine 52

Nuclear Medicine Radiopharmaceuticals Radiation Health Science 52

Imaging Technology

JUNE 26, 2023

For more than two decades, Mahmood has been involved in the development and implementation of new imaging methods for the examination of disease processes, with a focus on translatable technology and early therapeutic response assessment.

Nuclear Medicine 90

Nuclear Medicine Education Radiopharmaceuticals Hospital 90

Imaging Technology

JULY 25, 2023

By leveraging our expertise in radiopharmaceuticals, we aim to contribute to the early detection and accurate monitoring of epithelial-derived cancers. This further strengthens our commitment to production and development of novel radiopharmaceuticals to advance cancer treatments and quality of life for cancer patients."

Radiopharmaceuticals 95

Radiopharmaceuticals Imaging Pharmaceutical Disease 95